SYMD2 was found to promote the expression of P-glycoprotein (P-gp) also known as multidrug resistance protein 1 (MDR1) or ATP binding cassette B1 (ABCB1) in renal cell carcinoma (RCC) and CRC cells. Here, PGP is linked to renal cell carcinoma.